
Improving Quality of Life in Patients with Uncontrolled Atopic Dermatitis (AD): Tools for Timely Identification and Treatment
Read to learn more about what tools can help you identify your patients with uncontrolled AD
This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.
Adverse event reporting can be found at the bottom of the page.


Read to learn more about what tools can help you identify your patients with uncontrolled AD

Beyfortus®▼ (Nirsevimab)

Read to learn more about the burdens of uncontrolled AD.

Read to learn more about the concept of CLCI, how it manifests in atopic dermatitis and its impact on patients.

Beyfortus®▼ (nirsevimab)
MAT-XU-2305061 (v2.0) Date of preparation: February 2024